<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612454</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1434</org_study_id>
    <nct_id>NCT02612454</nct_id>
  </id_info>
  <brief_title>Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to &lt;18 Years of Age With Atopic Dermatitis (AD)</brief_title>
  <official_title>An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to &lt;18 Years of Age With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the long-term safety of dupilumab in
      pediatric participants with AD.

      The secondary objectives of the study are:

        -  To assess the long-term efficacy of dupilumab in pediatric participants with AD

        -  To assess the trough concentrations of functional dupilumab in serum and the
           immunogenicity in pediatric participants with AD after re-treatment with dupilumab.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 22, 2015</start_date>
  <completion_date type="Anticipated">October 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 16, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visit</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with at least one TEAE per participant year from baseline through the last study visit</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent serious adverse events (SAEs) from baseline through the last study visit</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs of special interest from baseline through the last study visit</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with an Investigator Global Assessment (IGA) score of 0 or 1 (clear or almost clear) at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Eczema Area and Severity Index (EASI)-75 (≥75% reduction in EASI from baseline of parent study) response at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EASI score at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in EASI at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body Surface Area (BSA) affected by AD (BSA) at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in SCORing Atopic Dermatitis (SCORAD) at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Children's Dermatology Life Quality Index (CDLQI) for participants ≥4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Infants' Dermatology Quality of Life Index (IDQOL) for participants &lt;4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders (defined as participants with IGA 0 or 1) who maintain IGA 0 or 1 during at least 75% of the subsequent* visits during the treatment period</measure>
    <time_frame>Baseline to week 260</time_frame>
    <description>*Subsequent refers to the visits following the first visit at which IGA 0 or 1 is achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For responders (defined as participants with IGA 0 or 1), median percentage of subsequent* visits during the treatment period, at which IGA 0 or 1 is maintained</measure>
    <time_frame>Baseline to week 260</time_frame>
    <description>*Subsequent refers to the visits following the first visit at which IGA 0 or 1 is achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AD flares during the study</measure>
    <time_frame>Baseline to week 272</time_frame>
    <description>AD flares are defined as worsening of the disease that requires escalation/intensification of AD treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualize event rate of AD flares during the study</measure>
    <time_frame>Baseline to week 272</time_frame>
    <description>AD flares are defined as worsening of the disease that requires escalation/intensification of AD treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with at least one flare during the study</measure>
    <time_frame>Baseline to week 272</time_frame>
    <description>AD flares are defined as worsening of the disease that requires escalation/intensification of AD treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of well-controlled weeks</measure>
    <time_frame>Baseline to week 272</time_frame>
    <description>Well-controlled weeks are those for which participants or parents/caregivers answer &quot;Yes&quot; AND during which no rescue treatments were administered</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">765</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Age ≥6 months to &lt;18 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged ≥6 months to &lt;18 years will receive dupilumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <arm_group_label>Age ≥6 months to &lt;18 years</arm_group_label>
    <other_name>DUPIXENT®</other_name>
    <other_name>REGN668</other_name>
    <other_name>SAR231893</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        1. Participated in a prior dupilumab study in pediatric patients with AD and adequately
        completed the visits and assessments required for both the treatment and follow-up periods,
        as defined in the prior study protocol

        Key Exclusion Criteria:

          1. Patients who, during their participation in a prior dupilumab study developed an
             adverse event (AE) or serious adverse event (SAE) deemed related to study drug which
             could indicate that continued treatment with study drug may present an unreasonable
             risk for the patient

          2. Patients, who during the participation in a prior Dupilumab study, developed an AE
             that was deemed related to study drug and led to study treatment discontinuation,
             which in the opinion of the investigator or medical monitor could indicate that
             continued treatment with study drug may present an unreasonable risk for the patient

          3. Treatment with an investigational drug, other than dupilumab, within 8 weeks or within
             5 half-lives (if known), whichever is longer, before the baseline visit

          4. Having used immunosuppressive/immunomodulating drugs within 4 weeks before the
             baseline visit

          5. Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit

          6. Diagnosed active endoparasitic infections or at high risk of these infections

          7. Severe concomitant illness(es) that, in the investigator's judgment, would adversely
             affect the patient's participation in the study.

        Note: Other protocol defined Inclusion / Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916-6103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206-2761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational site</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136-7028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401-3505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site 2</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2C 2N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Kutna Hora</city>
        <zip>28401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Prague</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Muenster</city>
        <state>North Rhine-Westphal</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Krakow</city>
        <state>Malopolska</state>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

